| Title |
Oxytocin nasal spray in fibromyalgic patients
|
|---|---|
| Published in |
Rheumatology International, February 2014
|
| DOI | 10.1007/s00296-014-2953-y |
| Pubmed ID | |
| Authors |
S. Mameli, G. M. Pisanu, S. Sardo, A. Marchi, A. Pili, M. Carboni, L. Minerba, G. Trincas, M. G. Carta, M. R. Melis, R. Agabio |
| Abstract |
Fibromyalgia is a pain disorder associated with frequent comorbid mood, anxiety, and sleep disorders. Despite the frequent use of a complex, poly-drug pharmacotherapy, treatment for fibromyalgia is of limited efficacy. Oxytocin has been reported to reduce the severity of pain, anxiety, and depression, and improve the quality of sleep, suggesting that it may be useful to treat fibromyalgia. To evaluate this hypothesis, 14 women affected by fibromyalgia and comorbid disorders, assuming a complex pharmacotherapy, were enrolled in a double-blind, crossover, randomized trial to receive oxytocin and placebo nasal spray daily for 3 weeks for each treatment. Order of treatment (placebo-oxytocin or oxytocin-placebo) was randomly assigned. Patients were visited once a week. At each visit, the following instruments were administered: an adverse drug reaction record card, Visual Analog Scale of Pain Intensity, Spielberger State Anxiety Inventory, Zung Self-rating Depression Scale, and SF-12. Women self-registered painkiller assumption, pain severity, and quality of sleep in a diary. Unlikely, oxytocin nasal spray (80 IU a day) did not induce positive therapeutic effects but resulted to be safe, devoid of toxicity, and easy to handle. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Egypt | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 100 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 17% |
| Student > Bachelor | 14 | 14% |
| Researcher | 12 | 12% |
| Student > Ph. D. Student | 12 | 12% |
| Student > Doctoral Student | 7 | 7% |
| Other | 17 | 17% |
| Unknown | 23 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 27% |
| Nursing and Health Professions | 12 | 12% |
| Psychology | 12 | 12% |
| Neuroscience | 7 | 7% |
| Agricultural and Biological Sciences | 4 | 4% |
| Other | 13 | 13% |
| Unknown | 26 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 November 2016.
All research outputs
#15,298,293
of 22,751,628 outputs
Outputs from Rheumatology International
#1,535
of 2,175 outputs
Outputs of similar age
#190,049
of 308,563 outputs
Outputs of similar age from Rheumatology International
#24
of 31 outputs
Altmetric has tracked 22,751,628 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,175 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,563 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.